Skip to main content
SpringerLink
Log in
Book cover

Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

  • Book
  • © 2014

Overview

Editors:
  1. Alexandre Trifilieff

    1. Respiratory Diseases Area, Novartis Institutes for BioMedical Reseach, Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Summarizes preclinical and clinical data

  • A valuable source of information for scientists and clinicians

  • Contemporary monograph on the pharmacotherapy of COPD

  • Includes supplementary material: sn.pub/extras

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages i-vii
    Download chapter PDF

  2. Current Pharmacotherapy for COPD

    • James F. Donohue, Matthew C. Miles, Jill A. Ohar
    Pages 1-23

  3. The Preclinical Pharmacology of Indacaterol

    • Alexandre Trifilieff, Steven J. Charlton, Robin A. Fairhurst
    Pages 25-37

  4. The Design of the Indacaterol Molecule

    • Robin A. Fairhurst, Steven J. Charlton, Alexandre Trifilieff
    Pages 39-65

  5. The Early Clinical Development of Indacaterol

    • Jutta Beier, Kai M. Beeh
    Pages 67-76

  6. INHANCE: An Adaptive Confirmatory Study with Dose Selection at Interim

    • David Lawrence, Frank Bretz, Stuart Pocock
    Pages 77-92

  7. Phase 3 Clinical Efficacy Studies: Lung Function

    • Ronald Dahl
    Pages 93-106

  8. Phase III Clinical Efficacy of Indacaterol: Patient-Centered Outcomes

    • Donald A. Mahler
    Pages 107-115

  9. The History and Performance of the Breezhaler Device

    • David Young, Lee Wood, Dilraj Singh, Juergen Dederichs
    Pages 117-128

  10. What Does the Future Hold for the Therapy of COPD?

    • Peter J. Barnes
    Pages 129-146
Back to top

Keywords

About this book

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Editors and Affiliations

  • Respiratory Diseases Area, Novartis Institutes for BioMedical Reseach, Basel, Switzerland

    Alexandre Trifilieff

Bibliographic Information

  • Book Title: Indacaterol

  • Book Subtitle: The First Once-daily Long-acting Beta2 Agonist for COPD

  • Editors: Alexandre Trifilieff

  • Series Title: Milestones in Drug Therapy

  • DOI: https://doi.org/10.1007/978-3-0348-0709-8

  • Publisher: Springer Basel

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Basel 2014

  • Hardcover ISBN: 978-3-0348-0708-1Published: 27 November 2013

  • eBook ISBN: 978-3-0348-0709-8Published: 19 November 2013

  • Series ISSN: 2296-6056

  • Series E-ISSN: 2296-6064

  • Edition Number: 1

  • Number of Pages: VII, 146

  • Number of Illustrations: 20 b/w illustrations, 21 illustrations in colour

  • Topics: Pharmacology/Toxicology, Pneumology/Respiratory System

Publish with us

Policies and ethics

Back to top

Search

Navigation